{"id":54721,"date":"2023-03-10T14:03:09","date_gmt":"2023-03-10T13:03:09","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/komodo-health-unveils-new-insights-in-early-onset-colorectal-cancer-at-white-house-cancer-moonshot-forum\/"},"modified":"2023-03-10T14:03:09","modified_gmt":"2023-03-10T13:03:09","slug":"komodo-health-unveils-new-insights-in-early-onset-colorectal-cancer-at-white-house-cancer-moonshot-forum","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/komodo-health-unveils-new-insights-in-early-onset-colorectal-cancer-at-white-house-cancer-moonshot-forum\/","title":{"rendered":"Komodo Health Unveils New Insights in Early-Onset Colorectal Cancer at White House Cancer Moonshot Forum"},"content":{"rendered":"
\n

\nKomodo\u2019s Healthcare Map and Technology Platform Are Increasingly Utilized to Close Gaps in Colorectal Cancer Screening; Research Collaboration Under Way With CDC<\/i>\n<\/p>\n

WASHINGTON–(BUSINESS WIRE)–Today, Komodo Health, a leading healthcare technology company, deepens its commitment to the White House Cancer Moonshot Initiative, joining patient advocates, industry innovators, federal policymakers, and public health officials to accelerate progress against colorectal cancer (CRC). During the meeting, Komodo will unveil new findings from its Healthcare Map supporting the need for earlier screening, which is especially urgent in light of pandemic-related impacts. While CRC screening rates have returned to the normal baseline, they have not made up for the 90% drop in colonoscopies seen in the spring of 2020, at the height of the pandemic.\n<\/p>\n

<\/a><\/p>\n

\nAs part of the company\u2019s research collaboration with the Centers for Disease Control and Prevention and Fight CRC, Komodo is evaluating the time from first screening to diagnosis across different screening modalities \u2014 examining how factors such as age, race, gender, geography, and other socioeconomic considerations play roles in CRC disparities. The research effort aims to drive insights at the federal level to improve early detection in the communities that need it most.\n<\/p>\n

\n\u201cPutting a spotlight around inequities in healthcare has never been more important, and colorectal cancer unfortunately paints a clear picture of how healthcare disparities play out in the real world,\u201d said Arif Nathoo, MD, CEO and Co-Founder of Komodo Health. \u201cWe know that insights from real-world data can play a valuable role in better supporting the incredible work of advocacy leaders like Fight CRC and efforts of President Biden\u2019s Moonshot Initiative. This coalition brings together a network of industry leaders to break down industry silos and drive us toward a new vision of what’s possible in colorectal cancer care.\u201d\n<\/p>\n

\nColorectal cancer is the second-leading cause of cancer deaths in the U.S. While CRC diagnoses and deaths have steadily declined in recent decades as a result of increased screening rates, rates of both continue to increase in younger patient populations, and stark location- and race-based disparities continue to put many Americans at higher risk. Insights from Komodo\u2019s Healthcare Map underscore the urgency of action among advocates, governments, and healthcare providers to improve early detection and access to care, especially because CRC presents in many different ways and can even be asymptomatic. Komodo\u2019s Fast Facts<\/i>: Colorectal Cancer<\/i><\/a>, also unveiled today, sheds additional light on trends in CRC screening, diagnosis, treatment, and care. Key findings on early-onset CRC trends include:\n<\/p>\n